ArticleMedical oncology (Northwood, London, England)2025
STXBP6 regulates growth, metastasis and lipid metabolism of ovarian cancer cells via the PI3K/AKT signaling pathway.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ovarian cancer (OC) is the primary cause of mortality related to cancers of the female reproductive system. Early diagnosis remains a major challenge, contributing to a high mortality rate and underscoring an urgent need for novel diagnostic approaches and effective therapeutic strategies. Here, we identify Syntaxin binding protein 6 (STXBP6) as a previously unrecognized oncogenic driver in OC. We demonstrate that STXBP6 expression is markedly elevated in OC tissues and cells and that it promotes OC growth and metastasis both in vitro and in vivo. RNA sequencing revealed that STXBP6 reprograms lipid metabolism, and mechanistic studies confirmed that it enhances OC progression through fatty acid oxidation (FAO). Moreover, activation of the PI3K/AKT signaling pathway was essential for STXBP6-driven FAO and malignant phenotypes. These findings uncover a novel STXBP6/PI3K/AKT axis, providing new insights into OC metabolic reprogramming and potential therapeutic targets.
Indexed as
Identifiers
41160169What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.